RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+8.21%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$337M
AUM Growth
+$337M
(+2.7%)
Cap. Flow
-$4.96M
Cap. Flow
% of AUM
-1.47%
Top 10 Holdings %
Top 10 Hldgs %
34.36%
Holding
108
New
18
Increased
35
Reduced
37
Closed
12
Top Buys
| 1 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
$11.4M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$9.62M |
| 3 |
CELG
Celgene Corp
CELG
|
$8.45M |
| 4 |
Cardinal Health
CAH
|
$6.79M |
| 5 |
AGN
Allergan plc
AGN
|
$5.58M |
Top Sells
| 1 |
Pfizer
PFE
|
$11.3M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$9.4M |
| 3 |
Gilead Sciences
GILD
|
$5.7M |
| 4 |
CFNL
Cardinal Financial Corp
CFNL
|
$5.03M |
| 5 |
FRX
FOREST LABORATORIES INC
FRX
|
$4.44M |
Sector Composition
| 1 | Healthcare | 85% |
| 2 | Financials | 1.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biogen
BIIB
$19.4B
| $15.8M | 4.68% | 50,000 +8,952 | +22% | +$2.82M |
|
|
COV
2
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
| $15.4M | 4.58% | 171,000 +126,779 | +287% | +$11.4M |
|
|
3
Gilead Sciences
GILD
$140B
| $14.9M | 4.43% | 180,000 -68,735 | -28% | -$5.7M |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $14.5M | 4.31% | 93,000 -18,731 | -17% | -$2.93M |
|
|
CELG
5
DELISTED
Celgene Corp
CELG
| $13.5M | 4% | 156,781 +98,390 | +169% | +$8.45M |
|
|
6
Vertex Pharmaceuticals
VRTX
$100B
| $9.62M | 2.85% | +101,600 | New | +$9.62M |
|
7
BioMarin Pharmaceuticals
BMRN
$11.2B
| $9.33M | 2.77% | 150,000 +4,736 | +3% | +$295K |
|
8
Alkermes
ALKS
$4.78B
| $8.46M | 2.51% | 168,000 -33,277 | -17% | -$1.67M |
|
9
Incyte
INCY
$16.5B
| $7.51M | 2.23% | 133,000 +25,962 | +24% | +$1.47M |
|
|
10
Cardinal Health
CAH
$35.5B
| $6.79M | 2.01% | +99,000 | New | +$6.79M |
|
|
AGN
11
DELISTED
ALLERGAN INC
AGN
| $6.77M | 2.01% | 40,000 +12,484 | +45% | +$2.11M |
|
|
12
Regeneron Pharmaceuticals
REGN
$61.5B
| $6.36M | 1.89% | 22,500 -33,292 | -60% | -$9.4M |
|
|
AGN
13
DELISTED
Allergan plc
AGN
| $5.58M | 1.65% | +25,000 | New | +$5.58M |
|
|
SLXP
14
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $5.37M | 1.59% | 43,493 -10,295 | -19% | -$1.27M |
|
15
Boston Scientific
BSX
$156B
| $5.3M | 1.57% | 415,000 +130,022 | +46% | +$1.66M |
|
16
Acadia Pharmaceuticals
ACAD
$4.38B
| $5.2M | 1.54% | 230,000 +53,117 | +30% | +$1.2M |
|
17
Cigna
CI
$80.3B
| $5.06M | 1.5% | 55,000 +5,865 | +12% | +$539K |
|
|
PCYC
18
DELISTED
PHARMACYCLICS INC
PCYC
| $4.93M | 1.46% | 55,000 -42,286 | -43% | -$3.79M |
|
19
Community Health Systems
CYH
$387M
| $4.63M | 1.37% | 102,000 +33,212 | +48% | +$1.51M |
|
|
CYBX
20
DELISTED
CYBERONICS INC
CYBX
| $4.62M | 1.37% | 74,000 +10,246 | +16% | +$640K |
|
21
Merck
MRK
$210B
| $4.51M | 1.34% | 78,000 +1,350 | +2% | +$78.1K |
|
22
Bristol-Myers Squibb
BMY
$96B
| $4.12M | 1.22% | 85,000 -1,815 | -2% | -$88K |
|
|
MDVN
23
DELISTED
MEDIVATION, INC.
MDVN
| $4.01M | 1.19% | 52,000 -52,505 | -50% | -$4.05M |
|
24
McKesson
MCK
$85.4B
| $4M | 1.19% | 21,500 -5,120 | -19% | -$954K |
|
25
Insulet
PODD
$23.9B
| $3.97M | 1.18% | 100,000 +41,039 | +70% | +$1.63M |
|